Da Fu
Impact in
- Cancer Research top 0.5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Molecular Biology top 2%
- Circular RNAs in diseases
- RNA modifications and cancer
- Ubiquitin and proteasome pathways
- Extracellular vesicles in disease
- Epigenetics and DNA Methylation
Papers in
-
- Circular RNAs in diseases 24
- RNA modifications and cancer 19
- Ubiquitin and proteasome pathways 13
-
- MicroRNA in disease regulation 34
- Cancer-related molecular mechanisms research 27
- Co-authors
- Yu‐Shui Ma (96 shared papers)Xizhong Shen (9 shared papers)Ting Yu (10 shared papers)Ying Fang (6 shared papers)Cui Sun (5 shared papers)Wen Li (18 shared papers)Zhongwei Lv (17 shared papers)Xiaodong Zheng (8 shared papers)
- Journals
- PLoS ONE (15 papers)Molecular Therapy — Oncolytics (6 papers)Technology in Cancer Research & Treatment (4 papers)Nature Communications (4 papers)Cell Biochemistry and Function (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Da Fu
163 papers receiving 5.1k citations
Da Fu's Hit Papers
Peers
Comparison fields: 5 of 134
- Cancer Research 1.6k
- Molecular Biology 2.8k
- Oncology 798
- Immunology 493
- Cell Biology 321
Countries citing papers authored by Da Fu
This map shows the geographic impact of Da Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Da Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Da Fu more than expected).
Fields of papers citing papers by Da Fu
This network shows the impact of papers produced by Da Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Da Fu. The network helps show where Da Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Da Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 168 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring Hit paper breakdown → | 2022 | 294 |
| 2 | 2006 | 190 | |
| 3 | 2011 | 117 | |
| 4 | 2018 | 112 | |
| 5 | 2022 | 112 | |
| 6 | 2015 | 106 | |
| 7 | 2016 | 103 | |
| 8 | 2023 | 102 | |
| 9 | 2010 | 102 | |
| 10 | 2011 | 98 | |
| 11 | 2019 | 94 | |
| 12 | 2018 | 92 | |
| 13 | 2021 | 90 | |
| 14 | 2018 | 85 | |
| 15 | 2017 | 85 | |
| 16 | 2013 | 83 | |
| 17 | 2019 | 80 | |
| 18 | 2013 | 72 | |
| 19 | 2014 | 69 | |
| 20 | 2011 | 67 |
About Da Fu
Da Fu is a scholar working on Molecular Biology, Cancer Research, Oncology, Plant Science and Cell Biology, having authored 168 papers that have together received 5.1k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (34 papers), Cancer-related molecular mechanisms research (27 papers), Circular RNAs in diseases (24 papers), RNA modifications and cancer (19 papers), Ubiquitin and proteasome pathways (13 papers), Plant-Microbe Interactions and Immunity (8 papers), Cancer Cells and Metastasis (7 papers) and Cancer Mechanisms and Therapy (7 papers). The work is most often cited by research in Cancer Research (1.6k citations), Molecular Biology (2.8k citations), Oncology (798 citations), Immunology (493 citations) and Cell Biology (321 citations). Da Fu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Yu‐Shui Ma, Xizhong Shen, Ting Yu, Ying Fang, Cui Sun, Wen Li, Zhongwei Lv, Xiaodong Zheng, Jibin Liu and Yi Shi. Their work appears in journals such as PLoS ONE, Molecular Therapy — Oncolytics, Technology in Cancer Research & Treatment, Nature Communications and Cell Biochemistry and Function.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.